News Release

Confirmation of the effect of mesenchymal stem cells on diabetes associated with cancer immunotherapy

Expanding the diagnostic reagent business and promoting the development of new diagnostic businesses. Investing in iXensor, a mobile health company in Taiwan.

Supporting well-being-oriented career development that starts with individual initiative and aspirations. The second cohort support for entrepreneurs within the company project, "Asuniwa project," has registered a new limited liability company.

Rohto's Report on Practicing Side Hustles, Concurrent Positions, and Intra-Corporate Entrepreneurship (2022)

Aichi Prefecture's Obu City, Nagoya University, Sugi Pharmacy, and Rohto Pharmaceutical have signed a memorandum of understanding regarding the "Obu City Child Myopia Prevention Project."

Notice of Payment of "Temporary Bonus"

Notice of Commencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202"

Participation in the Osaka Pavilion at the 2025 World Exposition in Japan (Osaka and Kansai Exposition)

We have been certified as a "Certified Health & Productivity Management Outstanding Organization 2022 (Large Corporation Category (White 500))" for our excellent health and productivity management implemented in collaboration with our employees.

Notice of Name Change for Consolidated Subsidiary "Nippon Eye Drop Research Institute Co., Ltd."